A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of the efficacy of Daytrana (methylphenidate transdermal system)
for the treatment of attention and behavioral symptoms in children with Autism Spectrum
Disorders. Twenty patients will be enrolled and treated with 10-30 mg of Daytrana for a total
of eight weeks. Changes in core hyperactivity, impulsivity, and inattention symptoms, autism
spectrum symptoms and functional outcomes will be assessed. Acceptability of the transdermal
route of administration in this population will also be assessed.
The researchers hypothesize that Daytrana is a safe and effective medication for children
with Autism Spectrum Disorders who have symptoms of inattention, hyperactivity and
impulsivity.